News
Phillippe Guillot-Chene, CEO of BioNet Europe, added, “We believe that BioNet’s RPV represents a transformative vaccine for preventing pertussis disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback